Azithromycin

is prescribed to treat:

• Respiratory tract infections (bronchitis, pneumonia, sinusitis) • Ear infections (otitis media) • Skin and soft tissue infections • Strep throat and tonsillitis • Sexually transmitted infections (chlamydia, gonorrhea) • Mycobacterium avium complex (MAC) in HIV/AIDS patients • Pertussis (whooping cough) • Certain stomach infections (H. pylori)

It is effective against many types of bacteria.

Azithromycin (Zithromax, Z-Pak) is a macrolide antibiotic used for community-acquired pneumonia, atypical respiratory pathogens, chlamydia, and certain skin and soft-tissue infections. It is among the most prescribed antibiotics in the United States, and it is also among the most prescribed for infections that are viral and will not respond to it at all.

Mechanism of Action

Azithromycin binds the 50S ribosomal subunit, blocking translocation during protein synthesis. It is bacteriostatic at typical concentrations — inhibiting growth rather than killing directly — which means the immune system does the final work, an important consideration in immunocompromised patients.

Its pharmacokinetics are unusual and account for the short course lengths. Azithromycin concentrates extensively inside cells, particularly phagocytes, which carry it to sites of infection and release it there. Tissue concentrations vastly exceed serum levels, and the terminal half-life is roughly 68 hours. A five-day course therefore delivers therapeutic tissue levels for around ten days, which is why the familiar five-day pack works and why dosing is once daily.

That same intracellular accumulation makes azithromycin effective against organisms that live inside cells — Chlamydia, Legionella, Mycoplasma — where beta-lactams such as amoxicillin cannot reach. This is its genuine niche.

Macrolide resistance among Streptococcus pneumoniae has risen substantially in the United States, which has narrowed azithromycin's role in respiratory infection and is the reason it is no longer recommended as monotherapy for pneumonia in most settings.

Clinical Use

Azithromycin is appropriate for atypical pneumonia, as part of combination therapy for community-acquired pneumonia requiring hospitalisation, for chlamydial infection, for pertussis, and for some traveller's diarrhoea. It is used in chronic suppression for bronchiectasis and certain COPD phenotypes, where the benefit appears partly anti-inflammatory rather than antimicrobial.

The larger issue is the volume of prescribing for acute bronchitis, sore throat, and upper respiratory illness — conditions that are overwhelmingly viral, where antibiotics neither shorten symptoms nor prevent complications. Acute bronchitis in an otherwise healthy adult is the single most common inappropriate antibiotic indication, and azithromycin is disproportionately the drug used, largely because a five-day pack feels like a low-commitment intervention.

It is not low-commitment. Every course selects for resistance, disrupts the microbiome, and carries individual risk. The antibiotic resistance article covers the broader stewardship picture, and the CDC antibiotic prescribing resource sets out which respiratory conditions warrant treatment. Our pulmonary team manages the respiratory conditions where suppressive macrolide therapy is genuinely indicated.

Cardiac Considerations

Azithromycin prolongs the QT interval and has been associated with a small absolute increase in cardiovascular death, concentrated in patients who already have cardiac risk factors. The FDA issued a specific warning about this.

The practical implication is not avoidance but selection. In a patient with known QT prolongation, significant electrolyte disturbance, bradycardia, or concurrent QT-prolonging drugs — certain antipsychotics, escitalopram at higher doses, some antiarrhythmics — the cumulative risk warrants either a different antibiotic or attention to potassium and magnesium first. In a healthy adult with no cardiac history, the absolute risk is very small.

This consideration is easy to overlook precisely because azithromycin feels routine. A five-day pack prescribed by phone to an older patient on several QT-prolonging medications is the scenario the warning is about.

Monitoring and Follow-Up

Short courses in healthy patients require no laboratory monitoring. The useful follow-up is clinical: is the patient improving within 48 to 72 hours? Failure to improve suggests a resistant organism, a viral illness that was never going to respond, or a complication, and the answer is reassessment rather than a second antibiotic.

Where cardiac risk factors exist, checking potassium and magnesium before or during treatment is reasonable, particularly in patients on diuretics.

Azithromycin has fewer drug interactions than older macrolides such as clarithromycin and erythromycin, because it is a much weaker CYP3A4 inhibitor. This is a genuine advantage in polypharmacy — it is a safer macrolide choice alongside statins, calcium channel blockers, and many other CYP3A4 substrates. It does, however, interact with warfarin, and INR warrants closer monitoring during and shortly after a course. The MedlinePlus azithromycin entry lists the interaction profile.

Gastrointestinal upset is the most common adverse effect. Severe or persistent watery diarrhoea during or in the weeks after a course raises the possibility of C. difficile and needs evaluation rather than antidiarrhoeal self-treatment.

Special Populations

In pregnancy azithromycin is used when indicated and has a reasonable safety record; it is the preferred agent for chlamydial infection in pregnancy. It is compatible with breastfeeding.

In older adults the cardiac considerations carry more weight, as do interactions and C. difficile risk. In significant hepatic impairment, caution applies since azithromycin is largely eliminated in bile; kidney impairment generally does not require adjustment. Patients with a history of cholestatic jaundice on a macrolide should not receive it again. A macrolide allergy is not a reason to avoid beta-lactams, and the two classes are structurally unrelated — a point sometimes confused when allergy lists are compiled.

The five-day pack deserves one further comment, because its convenience is part of the prescribing problem. A short, simple, well-tolerated course lowers the threshold for prescribing in a way that longer regimens do not, and patients come to expect it for illnesses where no antibiotic is warranted. Explaining that a viral bronchitis will run its two-to-three-week course regardless, and offering a specific plan for symptom relief and a threshold for returning, satisfies the underlying request more honestly than a prescription does. Patients are generally more accepting of this than clinicians expect.

When to Contact Your Doctor

Seek urgent care for palpitations, fainting, or an irregular heartbeat, particularly if you have cardiac disease or take other QT-prolonging medications. Report severe or persistent watery diarrhoea with abdominal cramping, during or up to several weeks after a course.

Yellowing of the skin or eyes, dark urine, or persistent nausea with abdominal pain may indicate liver injury. Any rash, especially a blistering or peeling rash or one with fever, needs immediate evaluation. Report failure to improve within two to three days, worsening fever, or new severe symptoms.

To discuss whether an antibiotic is needed for your illness, or to review an infection that is not improving, contact us or schedule a visit.